Biotech Values

[DewDiligence]

EGRX receives another patent on rapid-infusion Treanda:

http://finance.yahoo.com/news/eagle-pharmaceuticals-receives-patent-bendamustine-120000840.html

Eagle Pharmaceuticals, Inc….today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,144,568, which pertains to the use of the bendamustine hydrochloride (HCl) formulation administered in a 50mL bag within ten minutes (the “rapid infusion” product). The patent issued today expires on March 15, 2033.

This new patent, along with three previously issued Patents (Nos. 8,609,707, 9,000,021, and 9,034,908), further expands and protects Eagle’s bendamustine HCI intellectual property estate.

Rapid-infusion Treanda, which has been licensed to TEVA, is EGRX’s most important asset. The PDUFA date for this product candidate is 12/13/15.